Matching-adjusted indirect comparison of ribociclib + nonsteroidal aromatase inhibitor versus abemaciclib + endocrine therapy in hormone receptor-positive/HER2-negative early breast cancer

Aim: Ribociclib + nonsteroidal aromatase inhibitor (NSAI) and abemaciclib + endocrine therapy (ET) are approved for high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer based on data from the NATALEE and monarchE trials, respectively...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Stephen Chia, Jie Li, Fei Ma, Daniel Stellato, Andriy Danyliv, Ilia Ferrusi, Huilin Hu, Murat Akdere, Andreas Makris
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Becaris Publishing Limited 2025-08-01
coleção:	Journal of Comparative Effectiveness Research
Assuntos:	abemaciclib early breast cancer her2-negative hormone-receptor positive matching-adjusted indirect comparison ribociclib
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!